Next-Generation Rapid mRNA Vaccine CQA Analytics
Supported by:
6 March 2024
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
Watch this webinar on demand to learn how InDevR and their VaxArray multiplexed immunoassay platform empower Critical Quality Attribute (CQA) testing for multivalent mRNA vaccines.
Watch this webinar discussion for free
Analytical methods capable of rapidly and simultaneously assessing all components in multivalent vaccines become increasingly important with introduction of high-valency vaccines and rapid manufacturing platforms, particularly for nucleic acid-based vaccines. This presentation will focus on key applications of the microarray-based, multiplexed VaxArray platform in vaccine analytics, with a focus on how the technology can be effectively utilised throughout the development and clinical validation of multivalent mRNA vaccines. Using influenza mRNA vaccines as a case study, we present data from a variety of on market and in development VaxArray assays to highlight how the platform empowers cost-effective analytical development throughout mRNA vaccine product lifecycle.
Key learning points
- Learn why analytical methods developed for traditional monovalent vaccines (ELISA, SRID, & others) are a bottleneck for mRNA vaccine development and manufacturing
- Understand how InDevR utilises decades of multiplexed assay development and manufacturing experience to accelerate mRNA vaccine development
- Learn more about the ways InDevR continuously monitors and verifies assay kit performance for new strains semi-annually
- Understand how InDevR’s expert services team can develop custom off-the-shelf assays specific to your vaccine samples
- Ask InDevR Chief R&D Officer questions about analytical development challenges during vaccine lifecycle.
Register now to watch this on-demand webinar.
Erica Dawson, PhD, Chief R&D Officer, InDevR Dr. Erica Dawson has been integral in leading the research and development and transfer to manufacturing of InDevR products since 2006. Dr. Dawson manages InDevR’s cross-functional R&D, Engineering and Field Application Science teams, guiding and overseeing the development of the company’s extensive technology portfolio and related intellectual property. Additionally, she collaborates with Sales and Marketing, Contract Services, and Manufacturing to promote the commercial success of these technologies. Dr. Dawson has acted as program manager or principal investigator on many of InDevR’s government- and foundation-funded contracts and grants which have totalled ~$38M in non-dilutive funds over the company history. Dr. Dawson also successfully led the company in a successful 510(k) clearance in April 2019 for the FluChip-8G assay, a $14.7M effort funded by the Biomedical Advanced Research and Development Authority (BARDA). Dr. Dawson has 20 years’ experience in project/program management and medical device/life science tools development and lifecycle management. Dr. Dawson earned her Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill, holds a B.S. (summa cum laude) from Hartwick College in Oneonta, NY, and completed her postdoctoral training in influenza microarray-based diagnostics at the University of Colorado at Boulder. Erica has published a wide number of high impact scientific publications and is a named inventor on numerous issued or pending US and worldwide patents. Is the webinar free? Yes – there is no charge to watch the webinar. How long will the webinar be? This webinar will last up to an hour. What do I need to watch this webinar? All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.SPEAKER
FAQs
FAQs
